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A B S T R A C T
Besides its well-known role in cervical carcinoma, HPV is also suggested to be involved in lung cancer development. A
number of authors have been investigating the presence of HPV in histological materials. We used routine bronchial as-
pirates from 84 patients with lung carcinoma for DNA extraction and then performed polymerase chain reaction for
high-risk HPV types 16, 18 and 33. The results were compared to those obtained from buccal and eyelid mucosa. Only
three patients were positive for HPV in bronchial aspirates: one for HPV 16 type, one for HPV 18 type, and one for HPV
33. Our data indicated the low prevalence of HPV in patients with lung carcinomas in Croatia, therefore it seems un-
likely that HPV contributes to the development of lung carcinomas in this region.
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Introduction
The etiology of lung carcinoma is only partially re-
solved. The majority of tobacco users do not develop such
tumors and at least 10–15% of lung carcinomas occur in
non smokers1. Some studies suggested that HPV may
play an aetiologic role in bronchial carcinogenesis and
possibility of a latent HPV infection as a cocarcinogen
cannot be excluded2. High-risk genotypes, including HPV
16, 18 and 33 are associated with the cancer of the uter-
ine cervix3 but they can be also detected in cancers of the
upper aerodigestive tract, including cancers of the oral
cavity, larynx and oesophagus tract4–6. A study in Fin-
land7 reported HPV integration in cancers of the hypo-
pharynx, larynx, tongue and oral cavity and review of
Syrjanen showed that HPV was detected in 22% of bron-
chial carcinomas with wide racial and geographic varia-
tion from 0–100%2. Recent article of Klein and al. re-
viewed 53 publications and 4508 cases showing the mean
incidence of HPV in lung carcinoma was 24.5% and sug-
gested that HPV is the second most important cause of
lung cancer after cigarette smoking8. Those HPVs, which
are considered as high risk for the cancer development,
express the early oncoproteins E7 and E6. E7 inactivates
the cellular tumor suppressor protein Rb, while E6 pro-
tein binds to the host cellular tumor suppressor protein
p53 and triggers its degradation through the ubiquitin
pathway9. The inactivation of p53 by HPV-E6 is consid-
ered to play a crucial role in human carcinogenesis10.
Some studies showed that tracheal epithelial cells could
be immortalised by HPV18 E6 and E7 oncogenes. Simi-
lar experiments were carried out with bronchial epithe-
lial cells, which were immortalised by the HPV 16 E6 and
E7 oncogenes and showed terminal differentiation of the
keratinocytes but were not-tumorigenic in nude mice2.
The aim of our work was to study the prevalence of
high-risk HPV types 16, 18 and 33 in 84 bronchial aspi-
rates of lung carcinoma patients by PCR and to elucidate
whether the HPV infection is associated with lung cancer
development in Croatia. The incidence of bronchial carci-
noma in Croatia for the year 2005 was 2996 per 10000011.
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HPV prevalence in Croatia is unknown as in the most
other countries12. To our knowledge this is the first study
to examine HPV prevalence in cytological bronchial spec-
imens of lung cancers patients in Croatian population.
Materials and Methods
Patients and samples
Requests for specimens were consented by patients
and approved by the local Ethical Commissions. The
anamnestic data collected from the patient were: age,
sex, smoking habits (pack/years, 1 pack/year corresponds
to a pack of 20 cigarettes smoked daily over a period of 1
year). Cytological evaluation of 139 patients, who under-
went bronchoscopy in the University Hospital for Lung
Disease »Jordanovac«, Zagreb, Croatia during 2007–2008,
revealed 84 lung carcinomas. Bronchoscopy was done ac-
cording to the standard clinical procedure with a flexible
video fiberoptic bronchoscope and routine cytological
samples were taken (bronchial aspirates, bronchial bru-
shings and/or biopsy touch smear specimens). For bron-
chial aspirate specimens the pulmonary physician col-
lected fluid from endobronchial lesion. Buccal and eyelid
swabs were simultaneously collected, as control DNA,
just before bronchoscopy, from one side of inner cheek
and inner side of one lower eyelid respectively by the cot-
ton sticks. The cotton swabs with mucosal epithelial cells
were immediately soaked in 2 ml sterile physiological so-
lution (0.9% NaCl) in the sterile tube. On arrival at the
cytology laboratory, bronchial aspirates were primarily
processed for routine diagnostic purposes. The samples
were centrifuged and a part of the cell pellet with re-
maining liquid was used to prepare conventional cytolog-
ical smears. They are fixed on air and then subsequently
stained according to May-Grünwald-Giemsa. According
to the 2003 WHO classification of lung tumors, we classi-
fied lung cancers into four broad categories: squmous cell
carcinoma, adenocarcinoma, small cell carcinoma and
large cell carcinoma13. The residual material of bronchial
aspirate, together with buccal and eyelid swabs, were
transferred to another laboratory at the Croatian Insti-
tute for Brain Research, for DNA isolation and HPV
DNA detection.
Detection and typing of HPV DNA
The liquid with cells obtained either from bronchial
aspirates or buccal and eyelid swabs was transferred to
the microcentrifuge tubes and centrifuged at maximum
speed for 8 minutes. The supernatant was removed, leav-
ing collected cells at the bottom. By combining alkaline
and temperature lysis DNA was isolated14,15. Samples
were resuspended in 75 mL alkaline mixture of 25 mM
NaOH and 0.2 mM EDTA and incubated for 10 minutes
at 98°C. Afterwards, samples were vortexed and incu-
bated for 10 minutes at 98°C, followed by cooling 2 min-
utes on ice. Finally, the neutralizing solution containing
40 mM Tris-HCl pH 5.0 was added to every sample, the
same volume as the initial volume for alkaline lysis. This
corresponded to 75 mL of neutralizing solution making
total of 150 mL, respectively, PCR-ready DNA solution
which was stored at 4 °C. The quality of DNA was as-
sessed by performing sex chromosomes detection with
PCR16. The screen was based on the presence of ame-
logenin gene (AMEL) on both X and Y chromosomes
(AMELX and AMELY), whereas AMELY contains the
small deletion in the first intron, which is used to distin-
guish the sequences of X and Y chromosomes. Three pri-
mers used were SexX (5’-TCTCCTATACCACTTAGTCACT),
SexY (5’-GCCCAAAGTTAGTAATTTTACCT), and Sex-
Common (5’-CAGCTTCCCAGTTTAAGCTCT) enabling
the amplification of 330-bp PCR product from the X, and
218-bp from Y chromosome. HPV viral DNA was ampli-
fied with type specific primers flanking the E6 region to
identify the HPV subtype17. The forward primer (5´AAG-
GGCGTAACCGAAATCGGT-3) was common to the se-
quence of HPV 16, 18 and 33 DNA. The reverse primer
sequences for HPV 16, 18 and 33 were 5´-GTTTGC-
AGCTCTGTGCATA-3´, 5´-GTGTTCAGTTCCGTGCACA-
-3´ and 5´-GTCTCCAATGCTTGGCACA-3´ respectively,
amplifying 140-bp product for HPV 16 and 18, and 141-
-bp for HPV 33. The final PCR product was analyzed by
agarose gel electrophoresis.
Results
84 patients with the cytological diagnosis of lung can-
cer in bronchial aspirates and others bronhoscopic speci-
mens were analyzed in this study. There were 64 males
and 20 females from 46 to 85 years (mean 64.35±7.73
years). 73 had a history of cigarette smoking (mean
64.35±36.94 pack/years), while 11 were non-smokers.
Cytologic examination revealed 38 cases of squamous
cell carcinoma, 14 cases of adenocarcinoma, 14 small cell
carcinoma, 12 cases of large cell carcinoma and 4 cases of
mixed type carcinoma (small and large cell carcinoma).
Only three out of 84 bronchial aspirates showed the pres-
ence of HPV DNA by PCR. The bronchial specimen
tested positive for HPV 16 belonged to 69-year old male,
smoker (100 pack/years) with squamous and small cell
lung carcinoma.The bronchial aspirate specimen positive
for HPV 18 was from 71-year-old female, smoker (35
pack/years) with adenocarcinoma and her buccal mucosa
specimen was also HPV 18 positive. The bronchial aspi-
rate specimen positive for HPV 33 belonged to 72-year-
-old male, smoker (125 pack/years) with large cell lung
carcinoma. His buccal mucosa specimen was also HPV 33
positive. Buccal mucosa specimens were HPV positive in
two patients mentioned before and negative for 82 pa-
tients while eyelid mucosa specimens were HPV negative
for all 84 patients (Figure 1).
Discussion
The present study on a series of 84 lung carcinoma
patients indicated the low incidence of HPV infection in
cytological samples of lung carcinomas in these patients.
In other studies the prevalence of HPV in lung cancers
ranged from 0 to 100%2. Sample preparation may be one
B. Vrabec Branica et al.: Detection of High-risk HPV Types in Lung Carcinoma, Coll. Antropol. 34 (2010) 1: 159–162
160
of the factors responsible for variation in HPV preva-
lence. All previous studies of detection of HPV DNA in
lung carcinomas were made on histological tissue speci-
mens. This is the first study of HPV DNA detection from
cytological bronchoscopic specimens of lung cancer pa-
tients. When old samples were used, the detection rate of
HPV DNA decreased with sample aged. Fresh samples
obtained immediately yielded better results11. We chose
to isolate DNA immediately from the fresh cytological
samples of bronchial aspirates. This was expected to
avoid modified or fragmented DNA frequently obtained
from archival tissue due to formalin fixation of the histo-
logical samples. Moreover we implemented a simple pro-
tocol for human DNA isolation which enabled to isolate
DNA solution ready for PCR in less than a hour14,15.
The geographic and environmental factors including
education, economic and weather conditions may ac-
count for the variable results reported. One study sho-
wed that Chinese who lived in different areas showed dif-
ferent HPV infection prevalence18. Our results confirmed
low incidence of HPV infection in lung carcinomas in our
geographic area. In most European countries (Germany
0%, France 2.7%, Turkey 5%, Greece 0%), in America
5.9% and India 5% prevalence of high-risk HPVs in lung
cancers are low19. Another study in Greece showed com-
pletely opposite results with HPV positivity as high as
69%20. In northern Europe and Chile (29%) HPV infec-
tion rate seems to be higher: in Finland 41.7% in adeno-
carcinoma and 28.6% in squamous cell carcinoma and in
Norway in 49% of lung carcinoma19. The highest preva-
lence of HPV infection was detected in Asia. In Okinawa
in Japan HPV infection rates were 79% in squamous cell
carcinoma and 49% in adenocarcinoma21. In China the
prevalence of HPV16 infection was 26% and of HPV18
was 23.3% in non-small cell lung carcinoma18.
Our samples contained normal and cancer cells, the-
refore it was not possible to distinguish whether HPV ex-
clusively affected the tumor cells, a problem present also
in the studies which used tissue specimens21. HPV is fre-
quently ubiquitous and it infects a high percentage of
people, therefore HPV infection is as well reported in
normal lung with presence of HPV DNA in pneumocytes
and alveolar macrophages22. Moreover, the carcinogenic
role of HPV has been previously emphasized in vitro by
immortalization of bronchial cell lines21. Kinjo et al.23
has argued that HPV is not aetiologically involved in
lung carcinomas development but that HPV induces
squamous metaplasia in adenocarcinomas. Another ex-
planation for a low viral load might be a »hit and run«
mechanism, where the virus DNA may be lost after
transformation, as shown in studies on a bovine model
and as suggested in HPV 18 oncogenesis21.
Two of our three patients, whose bronchial aspirates
contained HPV DNA, had also HPV positive sample of
buccal mucosa. Today little is known about oral HPV in-
fection in the general population and in some popula-
tion-based, control studies of oral cancer, the prevalence
of HPV infection among control patient varied from 5.0%
to 9.2%24. HPV has been regarded as a sexually transmit-
ted disease but this view is challenged by frequent detec-
tion of HPV in children. Unlike in genital tract, natural
history of oral HPV infection is poorly studied25. HPV
can also be transmitted by non-sexual routes including
casual physical contact and perinatal vertical transmi-
ssion26. On the other hand, some authors suggested that
the oral cavity is a significant reservoir for HPV infection
that may not be entirely independent of the cervical
reservoir27. The prevalence of HPV 16/18 was even dem-
onstrated in the blood circulation of lung cancer patients
where it was significantly higher than that of the control
group. Still the possible route of HPV entering the blood
cells remained an enigma28.
In conclusion, in our experience with 84 bronchopul-
monary cancers, few cases of oncogenic HPV DNA were
detected suggesting HPV 16, 18 and 33 infections are un-
likely to contribute to lung carcinogenesis in Croatia,
similar to some other European countries. All three HPV
positive patients were smokers. It would be useful to de-
tect the presence of HPV in lung cancers in larger num-
ber of nonsmokers where we can see the effect of HPV
alone in the absence of other associated carcinogenic fac-
tors. Also it would be important to find the prevalence of
HPV in the general population.
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Fig. 1. Gel electrophoresis of PCR products of sex determination
(upper gel) and HPV detection (lower gel) obtained from samples
isolated from patients 1–3. Patient 1 was female positive for HPV
18, while patient 2 and 3 were males positive for HPV16 and 33
respectively (+denotes HPV positive samples, C+ positive control
obtained from the cervix of an unrelated patient). The samples
were taken from buccal (B) and eyelid (E) mucosa and bronchial
aspirates (A). SM – 100 bp DNA ladder as a size marker, no
DNA-negative control without DNA.
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ODRE\IVANJE HUMANOG PAPILOMA VIRUSA TIPA 16, 18 I 33 U ASPIRATIMA BRONHA
PACIJENATA S KARCINOMOM PLU]A METODOM LAN^ANE REAKCIJE POLIMERAZOM:
ISTRA@IVANJE 84 PACIJENATA U HRVATSKOJ
S A @ E T A K
Za humani papiloma virus je pretpostavljeno da mo`e imati, osim u etiologiji karcinoma cerviksa uterusa, ulogu i u
etiologiji nastanka karcinoma plu}a. Prisustvo visokorizi~nih tipova papiloma virusa tipa 16, 18 i 33 istra`ivano je u
rutinskim citolo{kim uzorcima aspirata bronha 84 pacijenata s karcinomom plu}a, nakon izolacije DNA, metodom
lan~ane reakcije polimerazom. Rezultati su uspore|ivani sa onima u uzorcima bukalne i vje|ne sluznice. Samo tri
pacijenta bila su pozitivna na humani papiloma virus: jedan na HPV 16 tip, jedan na HPV 18 tip i jedan na HPV 33 tip.
Na{i rezultati potvr|uju nisku prevalenciju humanog papiloma virusa u pacijenata s plu}nim karcinomom u Hrvatskoj
{to ukazuje da HPV vjerojatno ne sudjeluje u razvoju karcinoma plu}a na ovom podru~ju.
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